Evidence map›Paper›PMID 39065671›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Hiroki Matsumoto, Fukiko Hihara, Tomoko Tachibana, Masakazu Oikawa, Hisashi Suzuki, Ming-Rong Zhang, Tatsuya Higashi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mitsuhiro ShinadaFaculty of Science, Toho University, Funabashi 274-8510, Japan.ORCID 0000-0003-4244-8914
Masashi TakahashiFaculty of Science, Toho University, Funabashi 274-8510, Japan.
Chika IgarashiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hiroki MatsumotoInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.ORCID 0000-0003-4044-0281
Fukiko HiharaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Tomoko TachibanaFaculty of Science, Toho University, Funabashi 274-8510, Japan.
Masakazu OikawaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hisashi SuzukiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Ming-Rong ZhangInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Tatsuya HigashiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hiroaki KuriharaDepartment of Diagnostic Radiology, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.
Yukie YoshiiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Yoshihiro DoiFaculty of Science, Toho University, Funabashi 274-8510, Japan.

Funding

Japan Science and Technology Agency JPMJFR2116Japan Society for the Promotion of Science JP22H03031
6 · The paper itself

Abstract

Copper (Cu) is a critical element for cancer cell proliferation and considerably accumulates in the nucleus.

Indexed as

64Cu2+ complexes64Cu2+ ionscancercopper requirementPIXEtripodal amine ligands

Identifiers

PMID39065671
PMCPMC11280065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.